Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8720676 | Best Practice & Research Clinical Gastroenterology | 2016 | 17 Pages |
Abstract
Currently curative treatment for esophageal squamous cell cancer (ESCC) is possible only in patients with early-stage, usually asymptomatic disease. In Western countries, where the incidence of ESCC is relatively low, a screening of asymptomatic, average-risk population is untenable. In order to detect early-stage ESCC or its precursor lesions it is important to identify high-risk patients and consider endoscopic surveillance in these groups. These high-risk groups include patients after curative treatment for head and neck cancer, previous endoscopic resection of ESCC, caustic injury, and patients with tylosis or achalasia. This paper discuss the evidence and proposed method of endoscopy surveillance of these high-risk patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
A. (PhD Student), D. (Radiotherapy lead at the Institute of Oncology), A. (Head of Department of Head and Neck Cancer), M.F. (Head of Department of Cancer Prevention),